The SomaScan® Assay and oncology

Translational Dx: Virtual Summit

Featuring expert presentations on the latest advances in translational oncology tools.

Watch on demand

Enjoy live presentations, Q&A sessions, and networking to stay up to date on what’s new in the industry. Check out the virtual booths for more information on our organizations, products, technology, and a chance to meet with company representatives.

ABSTRACT

SOMAmer® Reagents are novel affinity binders made from single-stranded DNA engineered with aromatic hydrocarbon side chains. These reagents combine the best properties of antibodies and aptamers – high affinity to thousands of proteins and reproducibly produced synthetically. SomaLogic has developed a proteomic platform called the SomaScan Assay for biomarker discovery that transforms protein concentrations in a biological sample into a corresponding DNA signature that can be measured using DNA quantification technology. The SomaScan Assay has been used to identify signals as surrogates for clinical outcomes, discover proteins associated with disease states, and correlate protein measurements with genetic variants. Given that the platform measures thousands of human proteins simultaneously in biological samples at high throughput, the knowledge base being built is unparalleled. We will describe the utility of the SomaScan Assay in oncology applications.

SomaLogic-design-ideas-23

Sheri K. Wilcox, Ph.D

Scientific Liaison and Technical Services, SomaLogic Inc

Sheri K. Wilcox is Senior Director, Scientific Liaison and Technical Services, at SomaLogic, Inc. in Boulder, Colorado. She received her B.S. in Chemistry from Vanderbilt University in Nashville, Tennessee, in 1993 and her Ph.D. in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute in La Jolla, California, in 1999. She completed two years of post-doctoral studies at Pharmacia and Upjohn in Kalamazoo, Michigan, and then joined SomaLogic, Inc. in 2001, where she has been contributing to the generation and utility of novel protein affinity reagents based on Slow-Off rate Modified Aptamers (SOMAmer® Reagents) for over 19 years.

Share with colleagues

More webinars

WebinarUtilizing proteomic strategies to uncover novel biomarkers and mechanisms in heart failure 

Plasma proteomics is a powerful approach for discovering novel protein biomarkers of drug toxicity in various disease contexts. One such biomarker in cardiovascular disease is apolipoprotein M (ApoM), which plays a crucial role in lipid metabolism and transport and is known to have both anti-inflammatory and cardioprotective effects in the body. Studying ApoM using proteomics requires various approaches to understand its expression, modifications, interactions, and functions in the proteome.

Learn more

WebinarUsing plasma proteomics to understand Alzheimer’s and other brain diseases

Dr. Walker discusses how he integrates proteomic, genetic, brain imaging and cerebral spinal fluid biomarkers from initially cognitively normal individuals who later develop dementia, in order to discover novel blood-based biomarkers and mechanistically relevant proteins for therapeutic target prioritization.

Learn more

WebinarProteomics for precision neuroscience: The power of protein analysis

This webcast highlights how academic, industry and government researchers are directly measuring protein abundance and function via multiplex proteomics to build more detailed characterizations of the biological systems underlying neurodegenerative diseases.

Learn more

Explore webinars in our interactive viewer